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Abstract There is growing evidence supporting the role of
inflammation in early brain injury and cerebral vasospasm
following subarachnoid hemorrhage (SAH). Matrix metal-
loproteinases (MMPs) are released by inflammatory cells
and can mediate early brain injury via disruption of the
extracellular matrix and mediate vasospasm by cleaving
endothelin-1 into vasoactive fragments. We hypothesize
that inflammation marked by neutrophil elevation and
MMP-9 release in human SAH is associated with vaso-
spasm and with poor clinical outcome. We enrolled
consecutive SAH subjects (N=55), banked serial blood
and cerebrospinal fluid (CSF) samples, and evaluated their
3-month modified Rankin scores (mRS). Vasospasm was
defined as >50% vessel caliber reduction on angiography
6–8 days post-SAH. A poor outcome was defined as mRS>2.
We compared blood leukocyte and neutrophil counts during
post-SAH days 0–14 with respect to vasospasm and 3-month
outcome. In a subset of SAH subjects (N=35), we compared
blood and CSF MMP-9 by enzyme-linked immunosorbent
assay (ELISA) on post-SAH days 0–1, 2–3, 4–5, 6–8, and
10–14 with respect to vasospasm and to 3-month outcome.
Persistent elevation of blood leukocyte (p=0.0003) and
neutrophil (p=0.0002) counts during post-SAH days 0–14
are independently associated with vasospasm after adjust-
ment for major confounders. In the same time period, blood
neutrophil count (post-SAH days 2–3, p=0.018), blood
MMP-9 (post-SAH days 4–5, p=0.045), and CSF MMP-9
(post-SAH days 2–3, p=0.05) are associated with poor 3-
month SAH clinical outcome. Neutrophil count correlates
with blood MMP-9 (post-SAH days 6–8, R=0.39; p=0.055;
post-SAH days 10–14, R=0.79; p<0.0001), and blood
MMP-9 correlates with CSF MMP-9 (post-SAH days 4–5,
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e-mail: MingMing_Ning@hms.harvard.eduR=0.72; p=0.0002). Elevation of CSF MMP-9 during post-
SAH days 0–14 is associated with poor 3-month outcome (p
=0.0078). Neither CSF nor blood MMP-9 correlates with
vasospasm. Early rise in blood neutrophil count and blood
and CSF MMP-9 are associated with poor 3-month SAH
clinical outcome. In blood, neutrophil count correlates with
MMP-9 levels, suggesting that neutrophils may be an
important source of blood MMP-9 early in SAH. Similarly,
CSF and blood MMP-9 correlate positively early in the
course of SAH, suggesting that blood may be an important
source of CSF MMP-9. Blood and CSF MMP-9 are
associated with clinical outcome but not with vasospasm,
suggesting that MMP-9 may mediate brain injury indepen-
dent of vasospasm in SAH. Future in vitro studies are needed
to investigate the role of MMP-9 in SAH-related brain injury.
Larger clinical studies are needed to validate blood and CSF
MMP-9 as potential biomarkers for SAH outcome.
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Introduction
Spontaneous subarachnoid hemorrhage (SAH) is one of the
leading causes of neurologic morbidity and mortality, account-
ing for 27% of all stroke-related years of potential life lost
before age 65 [1]. SAH is associated with early brain injury,
which is the primary cause of mortality in SAH patients and
may be associated with the pathogenesis of cerebral
vasospasm [2]. Cerebral vasospasm is a known complication
of SAH and another important cause of morbidity and
mortality in SAH patients who survive aneurysm treatment
[3]. How early brain injury and cerebral vasospasm ultimately
affect long-term SAH outcome in human subjects remain
incompletely understood [4], and there are few clinical
molecular biomarkers for vasospasm and SAH outcome.
There is growing evidence that inflammation plays a key
role in early brain injury and cerebral vasospasm [2, 5, 6].
Elevation of leukocyte adhesion molecules and cytokines in
cerebrospinal fluid (CSF) and serum are associated with
changes in cerebral blood flow in SAH [7, 8]. Multiple
animal and cross-sectional human studies have reported
association between leukocytosis and the development of
vasospasm or ischemia [9–11] and poor outcome [12–15]
following SAH. The mechanism via which inflammation
causes narrowing of cerebral arteries and brain injury is
incompletely understood. Inflammatory cells such as
leukocytes are a major source of MMPs after brain injury
[16]. MMP-9, in particular, may mediate early brain injury
in SAH by causing neuronal apoptosis through disruption
of neuron–extracellular matrix interaction [17, 18]. MMPs
are also implicated in the disruption of blood–brain barrier
(BBB) integrity, progression of cerebral edema, and
worsening cerebral ischemic injury [19], all of which
may affect SAH clinical outcome. Furthermore, MMPs 2
and 9 can cleave big endothelin-1 (ET-1) into strongly
vasoactive segments which further promote neutrophilic
MMP release, creating a positive feedback loop that
potentially mediates cerebral vasospasm [20–22]. MMP-9
therefore may mediate a poor SAH outcome via different and
divergent pathogenic mechanisms and may be the link
between inflammation and the genesis of “spasmogens”
such as ET-1 in cerebral vasospasm following SAH. We
hypothesize inflammation marked by leukocyte and neutro-
phil elevation in SAH is associated with MMP-9 elevation in
blood and CSF, leading to vasospasm and worse SAH
clinical outcome, and that peripheral leukocyte and neutro-
phil counts and blood and CSF MMP-9 may be useful
biomarkers for vasospasm and outcome following SAH.
Methods
Subject Selection
Fifty five consecutive SAH patients within 96 h of spontaneous
SAH were prospectively enrolled, and their blood and available
CSF were sampled on post-SAH days 0–1, 2–3, 4–5, 6–8, and
10–14. CSF samples were acquired only from patients who had
an external ventricular drain (EVD) placed for clinical indica-
tions. Patients with traumatic SAH, pregnancy, end-stage renalor
hepatic disease, intracranial malignancies, or infectious menin-
gitis were excluded. We selected a subcohort of subjects with
both blood and CSF samples available for MMP-9 analysis
(N=35). All subjects were consented in accordance with
institutional review board approved protocols.
Daily peripheral leukocyte and neutrophil count is
extracted from subjects’ medical records. Per clinical
protocol, all SAH patients underwent daily complete blood
count measurement using automatic flow cytometry
(ADVIA 120, Siemens) by CLIO-certified clinical labora-
tory. For subjects who had more than one measurement on
a single day, the highest measurement was recorded.
BloodsamplesforMMP-9analysiswerecollectedinheparin-
coated tubes and immediately centrifuged at 3,900 rpm for
15 min, aliquotted, and then stored frozen at −80°C until
analysis. CSF samples were collected under sterile conditions
over 30 min from the anti-reflux burette in the EVD system.
Upon collection, all samples were immediately centrifuged
(3,900 rpm, 15 min at room temperature) and separated from
cellular debris, aliquoted, and stored frozen at −80°C.
Total MMP-9 (active plus pro-MMP-9; R&D Systems,
Minneapolis, MN) were measured using solid-phase ELISA
by blinded investigators. All assays were run in duplicates
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performed to assess MMP-9 activity and isoforms via
previously described methods [23].
Angiographic vasospasm was defined as >50% reduction
in diameter of any vessel on angiography on post-SAH days
6–8. Per institutional protocol, all SAH patients underwent
digital subtraction cerebral angiography (DSCA) upon initial
presentation and then again on post-SAH days 6–8 for
evaluationofangiographicvasospasm.Severity ofvasospasm
was determined by comparing subsequent to baseline DSCA.
Thetotalnumberofvesselsegmentswithvasospasticchanges
did not affect the grading of vasospasm. When multiple
vessels were involved, subjects were classified based on the
most severely affected vessel. Subjects who had several
subsequent DSCAs were classified according to the most
severe vasospasm seen among all DSCA.
Long-term functional outcome at 3-month post-SAH
were prospectively assessed using modified Rankin score
(mRS) via telephone interview. A standardized question-
naire was used to perform mRS scoring to reduce inter-rater
variability. A poor outcome was defined as mRS>2.
Statistical Analysis
Continuous variables were compared using two-tailed
Student’st-test or Wilcoxon rank sum test depending on data
normality. Depending on data normality, Pearson or Spearman
correlation was used to measure strength of association
between continuous variables. Categorical variables were
compared using Chi-square test. We used longitudinal regres-
sion analysis to model data with repeated measurements. All
statisticalanalyseswereperformedusingJMP8.0andSAS9.2.
Results
Baseline Characteristics
Subject characteristics of the entire SAH cohort (n=55) are
summarized in Table 1. Mean age, gender distribution,
aneurysm locations, and incidences of vasospasm and poor
outcome are comparable between the large SAH cohorts
and the subset of subjects selected for MMP-9 analysis. Of
the overall cohort, 49% presented with Hunt and Hess (HH)
grade of 3 and above, whereas 60% of the MMP-9
subcohort presented with HH grade of 3 and above. The
large majority of subjects have Fisher grade 3 SAH.
Elevated Blood Leukocyte and Neutrophil Counts
are Associated with Vasospasm
Subjects who developed angiographic vasospasm have higher
leukocyte counts throughout post-SAH days 0–14 (p=0.0003;
Fig. 1). Individually, elevated peripheral leukocyte counts on
post-SAH days 2 (p=0.037),3(p=0.046),4(p=0.028), 5
(p=0.025), 6 (p=0.036), 7 (p=0.0018), 8 (p=0.0097), 9
(p=0.0007), 10 (p=0.0003), and 11 (p=0.019) are
associated with angiographic vasospasm. After adjustment
for potential confounders including HH grade, age, and
modality of SAH surgical treatment, elevated leukocyte
counts throughout post-SAH days 0–14 remain indepen-
dently associated with vasospasm (p=0.0003).
We also examined a specific subset of leukocytes —
neutrophils.Subjectswhodevelopedangiographicvasospasm
have higher neutrophil counts throughout post-SAH days 0–
14 (p=0.0027; Fig. 2). Individually, elevated peripheral
neutrophil counts on post-SAH days 0–1( p=0.018) and 6–
8( p=0.0005) are associated with the development of
angiographic vasospasm. After adjustment for potential
confounders including HH grade, age, and modality of SAH
surgical treatment, elevated neutrophil counts throughout
Table 1 Baseline characteristics of study cohort
Characteristics (N=55)
Age (mean years) 53 (+/− 16)
Female Gender (%) 31 (56%)
Hunt and Hess Grade
1 7 (13%)
2 21 (38%)
3 13 (24%)
4 9 (16%)
5 5 (9%)
Fisher Grade
1 3 (5%)
2 11 (20%)
3 38 (69%)
4 3 (5%)
Aneurysm Location
Acom 21 (38%)
Pcom 11 (20%)
Angio Negative 10 (18%)
ICA 3 (5%)
PICA 4 (7%)
MCA 3 (5%)
Basilar 1 (2%)
ACA 2 (4%)
Angiographic Vasospasm 22 (60%)
3-month Outcome
mRS>2 (bad) 15 (28%)
mRS≤2 (good) 39 (72%)
6-month Outcome
mRS>2 (bad) 10 (20%)
mRS≤2 (good) 41 (80%)
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vasospasm (p=0.0002).
Elevated Neutrophil Count, Blood, and CSF MMP-9
are Associated with Poor 3-month SAH Outcome
Persistent blood neutrophil elevation throughout post-SAH
days 0–14 is associated with poor 3-month SAH outcome
(mRS>2; p=0.018). Individually, elevated neutrophil count
on post-SAH days 2–3 is associated with poor 3-month
SAH outcome (p=0.018; Fig. 3).
Persistent blood MMP-9 elevation throughout post-SAH
days 0–14 showed a trend towards association with 3-month
SAH outcome in a longitudinal regression model (p=0.09).
Specifically, elevated blood MMP-9 on post-SAH days 4–5i s
associated with poor 3-month SAH outcome (p=0.045; Fig. 4a).
MMP-9 is detectable in CSF at levels approximately
200-fold lower than that in blood. Zymogram confirmed
that the MMP-9 present in the CSF is enzymatically active
[24], suggesting that it could functionally participate in the
events triggered by SAH. Persistent elevation of CSF
MMP-9 throughout post-SAH days 0–14 is associated with
poor 3-month SAH outcome (p=0.0078). Specifically,
elevated CSF MMP-9 on post-SAH days 2–3( p=0.05) is
associated with poor 3-month outcome (Fig. 4b).
Neutrophil Counts, Blood MMP-9, and CSF MMP-9
Correlations
In blood, neutrophil counts correlate with MMP-9 levels on
post-SAH days 6–8( R=0.39; p=0.055, Fig. 5a) and post-
SAH days 10–14 (R=0.79; p<0.0001, Fig. 5b). CSF
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Fig. 1 Peripheral white blood
cell count is elevated in SAH
subjects with angiographic
vasospasm (VSP+; n=22)
compared with those without
Vasospasm (VSP-; n=33) during
post-SAH days 0–14 (p=0.0003).
* indicates between-group
difference on that specific post-
SAH day is significant at a level
of p<0.05
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(R=0.72;p=0.0002; Fig. 6). However, neither CSF (p=0.32)
nor blood MMP-9 (p=0.42) were associated with angio-
graphic vasospasm on statistical analysis (Fig. 7).
Discussion
We found that early elevation of blood neutrophil count is
associated with both cerebral vasospasm and poor 3-month
clinical outcome after SAH, and both blood and CSF MMP-9
are associated with poor 3-month SAH clinical outcome but
not with vasospasm. Early blood neutrophil count is associ-
ated with blood MMP-9 levels, suggesting that neutrophils
may be an important source of blood MMP-9. Similarly, early
blood MMP-9 elevation is associated with CSF MMP-9
elevation while blood MMP-9 levels are 200-fold higher than
CSF MMP-9 levels, suggesting that blood MMP-9 may be an
important source of CSF MMP-9 early in SAH.
Recent studies suggest MMPs may participate in the
pathogenesis of cerebral vasospasm and early brain injury
in multiple pathways. Activation of MMP-9 is associated
with endothelial apoptosis, which plays an important role in
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604 Transl. Stroke Res. (2011) 2:600–607cerebral ischemia after SAH [25]. Furthermore, there is
growing evidence supporting the important role of initial
global ischemia in brain injury following SAH [25]. MMPs
are known to play important and different roles in acute
ischemic brain injuries as well as in brain recovery from
such injuries. Elevation of MMPs is associated with worse
clinical outcome in acute peri-stroke phase while subacute
MMP elevation promotes remodeling and recovery follow-
ing ischemic injury [26]. In concordance with these studies,
we showed for the first time that early elevation of MMP-9
in CSF is associated with poor 3-month clinical outcome in
human SAH subjects. Although we are unable to establish
the source of CSF MMP-9 in this clinical study, our data
suggest that MMP-9 likely plays an important role in early
brain injury following SAH.
We also found a positive correlation between blood
and CSF MMP-9 levels early in SAH course. Given their
relative concentrations, it is conceivable that this positive
correlation may represent blood MMP-9 leaking across
the BBB into CSF. Whether blood and CSF MMP-9 play
a direct pathogenic role in early brain injury or act as a
surrogate for poor outcome mediated by degree of BBB
disruption will need to be determined by more mecha-
nistic in vitro studies. In our data, while MMP-9 in
blood and CSF are associated with poor SAH outcome,
they are not associated with angiographic vasospasm,
s u g g e s t i n gt h a tM M P - 9m a yl e a dt ob r a i ni n j u r y
independent of vasospasm. These results support the
growing hypothesis that there may be divergent patho-
physiologic pathways leading to angiographic vasospasm
and poor outcome in SAH [27, 28].
We also demonstrated, for the first time in humans, that
elevation of peripheral neutrophil count is associated with
both vasospasm and poor outcome in SAH. Prior clinical
studies have established that blood leukocyte elevation at
single time points are associated with cerebral vasospasm
[9, 14], which we replicated in our study. However, none of
these studies specifically examined neutrophils. Data from
our study support results from animal studies demonstrating
that reduced neutrophil activity is associated with less brain
injury and better outcome in SAH [29, 30]. The correlation
between early neutrophil elevation and blood MMP-9
elevation raise the possibility that neutrophils may mediate
poor SAH outcome partly via MMP-9 release.
Our study has several caveats, the most important one
being that this is an observational association study. While we
carefully studied a prospective and well-phenotyped SAH
cohort with longitudinal temporal data and measured MMP-9
inCSFaswellasinblood,theoverallsamplesizeofthisstudy
is modest. With a small sample size, we have no power to
meaningfully adjust for all confounders or to perform subset
analysis. Given the modest sample size, we limited the risk of
multiple comparisons by focusing on a single molecular
marker — MMP-9, a major product of neutrophils, in two
compartments (blood and ventricular CSF). However, we
recognize that SAH-related early brain injury is likely
associated with changes in multiple interacting molecular
pathways.Our datasupport MMP-9 asa potentially important
mediator of poor SAH outcome, but we cannot comment on
the specific pathophysiologic mechanism connecting MMP-9
and brain injury. For example, other important MMPs, in
particular, the other gelatinase — MMP-2, is also known to
mediate important neuroinflammatory responses [31, 32]a n d
chronic vascular inflammatory processes such as vascular
cognitive impairment [33]. In this exploratory study, we
chose to focus on the acute inflammatory cascade involving
the neutrophil — MMP-9 axis — because neutrophils are
major sources of MMP-9 but not of MMP-2 [34]. We
acknowledge that MMP-2 may very well play a role in
SAH-related cerebral injury and will examine MMP-2 in
the future.
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Fig. 7 a Blood MMP-9 levels during post-SAH days 0–14 in SAH
patients showed no association with presence (VSP+; n=17) or
absence of angiographic vasospasm (VSP-; n=16; p=0.42). b CSF
MMP-9 levels during post-SAH days 0–14 in SAH patients showed
no association with presence (VSP+; n=17) or absence of angio-
graphic vasospasm (VSP-; n=15; p=0.32)
Transl. Stroke Res. (2011) 2:600–607 605Clinically, due to patient safety considerations, we were
only able to sample SAH subjects’ blood at four time points
between post-SAH days 0–14, and sample CSF only from
EVD systems. This limits our ability to measure and
correlate blood and CSF leukocyte and neutrophil counts
reliably to examine the time course and degree of
inflammation within the CSF compartment and its contri-
bution to MMP-9 release in SAH. Moreover, we can only
collect CSF samples from subjects who had EVD place-
ment and CSF drainage for a clinical indication due to
ethical considerations. This subset of subjects with both
CSF and blood samples available were chosen for MMP-9
analysis. This may bias the selection of subjects for CSF
biomarker study to those with clinical symptoms of
hydrocephalus and those with higher HH grade, and
thereby limit the generalizability of our results. In summary,
while results from this initial study suggest that early
peripheral inflammatory response and MMP-9 may be an
important predictor of SAH clinical outcome, larger
prospective studies, studies of other molecular mediators
of SAH outcome, and in-depth bench studies are needed to
understand and validate these findings.
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